Biotech entity
The clearest coverage concentration is gene-therapy: 4 of 5 stories, with the rest divided among 1 other category. uniQure is the most frequent co-covered peer, appearing in 3 of the 5 tracked stories. The 156-day window averages about 0.2 stories each week. The busiest single day carried 2.
Last mentioned: Aug 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 40 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is gene-therapy: 4 of 5 stories, with the rest divided among 1 other category. uniQure is the most frequent co-covered peer, appearing in 3 of the 5 tracked stories. The 156-day window averages about 0.2 stories each week. The busiest single day carried 2. Sentiment skews less negative than the wider beat, at 0% negative against 20% across all 551 Biotech stories in the same window. They are less corroborated than the beat average, carrying 2.2 original sources each against 3.7 for the same window. Their average consequence score of 6 runs below the beat's 6.2 for that window. We currently track 5 Biotech stories that mention AMT-130, published between March 3, 2026 and August 5, 2026.
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 551 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AMT-130. Shared-story counts are live from our verified record — not editorial picks.
Four-Year Follow-Up Data from AMT-130 Pivotal Study
Durability of gene therapy effect expected to be reported, a key factor for regulatory decisions.
Regulatory Submissions for AMT-130 in Huntington's Disease (Planned)
uniQure aims to file for U.S. and U.K. approval in Q3 2026, targeting accelerated pathways.
FDA accepts AMT-130 Phase 1/2 data for BLA
The FDA reversed its earlier requirement for additional data, agreeing existing clinical data supports a near-term BLA submission for Huntington’s gene therapy.
SEC filings and market close
Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions.
Insider sales executed
Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06.
AMT-260 Preliminary Data and AMT-191 Further Analyses
Six-month follow-up from the Phase I/IIa AMT-260 trial in epilepsy and new Fabry data presented.
Q1 2026 earnings
uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative.
FDA Type B Meeting
Planned follow-up meeting to define the Phase III pathway for AMT-130 in Huntington's disease.
RBC upgrade
RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35.
Earnings Release
Company announces 2025 results and provides update on FDA Type A meeting.
Updated AMT-191 Phase I/II Data in Fabry Disease
Interim data demonstrate sustained enzyme activity and safety in Fabry disease patients.
AMT-260 Data
Clinical data expected from the Phase I/IIa study in refractory mesial temporal lobe epilepsy.
Planned BLA submission in Q3 2026
UniQure intends to submit a Biologics License Application for AMT-130 in the third quarter, pending alignment meeting on confirmatory study design.
Fiscal Year End
uniQure closes 2025 with $622.5M in cash and equivalents.
Positive Topline Data for AMT-130 in Huntington's Disease
uniQure reports positive pivotal Phase I/II data, showing statistically significant improvements in disease markers.
Three uniQure directors each offloaded 1,993 shares at $27.06, pocketing a combined $162K. The gene therapy company’s stock trades above key moving averages after an RBC upgrade, but sales hint at insider caution amid heavy cash burn.
Source: dailypolitical.com · themarketsdaily.com
uniQure's AMT-130 for Huntington's disease is on track for U.S. and U.K. regulatory filings in Q3 2026, following positive pivotal data. Pipeline updates for AMT-191 and AMT-260 in Fabry disease and epilepsy show a broadening gene therapy platform.
Source: rttnews.com · finanzen.ch
FDA’s acceptance of existing clinical data for uniQure’s AMT-130 gene therapy signals a major regulatory win, with the company on track for a BLA submission in Q3 2026 and a potential first-in-class approval for Huntington’s disease.
uniQure’s AMT-130 update validates its gene therapy platform, while NTHI’s NEO212 advancement and an acquisition deal spotlight a busy week for biotech pipelines and dealmaking.
Source: Prabha Kurup (us) · Prabha Kurup (us)
uniQure reported a robust $622.5 million cash position, extending its operational runway into late 2029. While clinical data for its Huntington’s disease candidate AMT-130 remains strong, the company is still seeking regulatory alignment with the FDA on a definitive Phase III pathway.
AMT-130 is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
